Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

NCT03529422 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Larynx
Lip
Oral Cancer
Digestive Organs--Diseases

Interventions

DRUG: Durvalumab
RADIATION: Intensity Modulated Radiotherapy Treatments

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]